Howe & Rusling’s VYNE Therapeutics VYNE Stock Holding History

Howe & Rusling’s Portfolio VYNE Stock Details VYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-2	Closed	–	–	1035
2022 Q3	$0	Buy	+2	New	+$13	﹤0.01%	1202

Other funds holding VYNE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

CAN

Cetera Advisor Networks El Segundo, California $20.2B AUM 22.31% 1-Year Est. Return

Howe & Rusling's VYNE Position: Q4 2022 in Review

Howe & Rusling sold out of VYNE Therapeutics (VYNE) in Q4 2022, closing a stake of 2 shares.

Howe & Rusling first reported a position in VYNE in Q3 2022 and held it in 1 quarter. The position peaked at $0 in Q3 2022. 41 funds tracked by Wall St. Rank hold VYNE as of Q4 2022.

Howe & Rusling reported no remaining VYNE Therapeutics position as of Q4 2022 after selling out during the quarter.
Howe & Rusling sold 2 VYNE Therapeutics shares in Q4 2022.
Howe & Rusling first reported a position in VYNE Therapeutics in Q3 2022 and held it in 1 quarter.
Howe & Rusling's VYNE Therapeutics position peaked at $0 in Q3 2022.
41 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q4 2022.

Based on Howe & Rusling's 13F filing for Q4 2022, filed 15 Feb 2023.